Compare GSK plc (GSK) vs Blue Owl Capital Inc. Class A Common Stock (OWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Blue Owl Capital Inc. Class A Common Stock — how do they compare? GSK plc trades at $47.87 (market cap $92.78B), while Blue Owl Capital Inc. Class A Common Stock trades at $8.79 (market cap $6.35B). The key difference: GSK plc is far larger — about 14.6× Blue Owl Capital Inc. Class A Common Stock's market cap, and Blue Owl Capital Inc. Class A Common Stock pays the higher dividend (9.8%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Blue Owl Capital Inc. Class A Common Stock for 0 Days on average.
| GSK | OWL | |
|---|---|---|
Market Cap | $92.78B | $6.35B |
Volume | 5,756,402 | 15,716,423 |
Sector | Health | Financials |
52-Week High | $61.18 | $17.17 |
52-Week Low | $43.24 | $8.23 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $112.77B | $10.53B |
Dividend Yield | 3.92% | 9.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →
